Ian Paul Everall

---

Ian Paul Everall (born August 1961 in Staffordshire, UK) is a British psychiatrist and neuropathologist best known for his work in HIV-associated neurocognitive disorders, and the cellular and molecular neuroscience of major psychiatric disorders including schizophrenia and autism spectrum disorder.... In 2017, he was appointed Executive Dean of the Institute of Psychiatry, Psychology and Neuroscience(IoPPN) at King’s College London, and is taking up his position in September 2017.

Biography

Everall studied Medical Sciences at the University of Leicester, receiving his BSC (Hons) in 1982 and qualifying in medicine in 1985. He then trained in psychiatry at the Bethlem Royal Hospital and Maudsley Hospital in London. In 1989, Everall was awarded a Medical Research Council (MRC) Clinical Research Training Fellowship at the Institute of Psychiatry (IoP; now known as the IoPPN), during which he discovered that HIV was associated with neuronal death. He earned a PhD in neuropathology (Neuronal Loss in HIV Infection: An investigation of the Distribution and Mechanism) in 1992 from the University of London.

In 1993, Everall was also appointed Senior Lecturer at the IoP and Honorary Consultant Psychiatrist at the South London and Maudsley NHS Trust, before becoming Professor of Experimental Neuropathology and Psychiatry at the IoP in 1999. He was elected as a Fellow of the Royal College of Psychiatrists and Royal College of Pathologists in 2004, and a Fellow of the Royal Australian and New Zealand College of Psychiatrists in 2010.

From 2004, he spent 6 years at the University of California in San Diego as a Professor of Psychiatry investigating compounds to protect neurons against HIV toxicity. At the end of 2009, he moved to Australia to take up a position as Cato Chair of Psychiatry and Head of the Department of Psychiatry at the University of Melbourne, studying molecular and cellular changes in the brain in major psychiatric disorders. In 2014, he was awarded a Doctor of Science for Investigations into the molecular and cellular neuropathology of psychiatric disorders. He was also made Director of Research for North West Mental Health—the largest provider of public mental health services in Australia—and served on the Board of Directors for the National Ageing Research Institute and Phoenix Australia (the national Centre for Posttraumatic Mental Health).

Everall is currently conducting research to improve mental health services and research capacity in 15 countries in the Asia-Pacific region He also involved in organising psychiatry training programmes for trainee psychiatrists

Research

In 2006, Everall patented the use of Selenium-binding protein 1 as a biomarker for the diagnosis of neuropsychiatric disorders. In 2012, he also helped to develop a gene based classifier for the diagnosis of autism that can predict with 75% accuracy whether an individual from a central European background has autism

Everall is the author of over 170 research papers in high impact journals including Nature Medicine, The Lancet, and Molecular Psychiatry. He has also published several books including: The Neurology of AIDS (Oxford University Press, 2012), The Postmortem Brain in Psychiatric Research (Kluwer Academic, 2002), and HIV Associated Dementia (Glaxo-Wellcome, 1999).

Everall is currently working on research into blood based biomarkers to help in the diagnosis of psychosis and autism spectrum disorder, and further refining the molecular neuropathology of schizophrenia.

References

This article "Ian Paul Everall" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Ian Paul Everall. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

---